Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | BCL9 | O00512 | 1/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035554 | 0.90 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19BCL9 | |
| SCHEMBL31198753 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ADRD2CYP2C19 | |
| SCHEMBL6749252 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19BCL9 | |
| SCHEMBL6745682 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ADRD2CYP2C19 | |
| SCHEMBL7502284 | 0.86 | BCL9 (0.62) | SMN1; SMN2NPC1RAB9ADRD2CYP2C19 | |
| SCHEMBL6749001 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL8316925 | 0.84 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19PDE4B | |
| SCHEMBL12251452 | 0.84 | BCL9 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19BCL9 | |
| SCHEMBL6752005 | 0.84 | HTT (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19BCL9 | |
| SCHEMBL31198939 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ADRD2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2177526-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 | Taisho Pharmaceutical Co. Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| CN-1061977-C | Aryl substituted heterocycles | ZENECA LTD (GB) | 2001-02-14 | — | — | CN | disclosed |
| EP-0630887-B1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LTD (GB) | 1999-07-28 | — | — | EP | disclosed |
| US-5654299-A | TREATING RESPIRATORY SYSTEM DISORDER (I.E. ASTHMA) WITH NEUROKININ 2 RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | disclosed |
| EP-0630887-A1 | 4-(aryl-substituted)-piperidines as neurokinin receptor antagonists | ZENECA LIMITED (GB) | 1994-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | SMN1; SMN2 3679/4885NPC1 3703/4885RAB9A 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.